Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 19, 2022, Brickell Biotech, Inc. (the "Company") received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") stating that the previously disclosed departure of Dennison T. Veru from the Company's Board of Directors (the "Board") resulted in noncompliance with the independent director and audit committee requirements set forth in Nasdaq Listing Rule 5605. More specifically, the Board currently is not comprised of a majority of "independent directors" within the meaning of Nasdaq Listing Rule 5605(a)(2), and the Board's Audit Committee does not have at least three members, each of whom is independent and meets the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as required by Nasdaq Listing Rule 5605(c)(2)(A). Currently, the Board has two independent members and two non-independent members, and the Audit Committee consists of the two independent members.

The Notice states that, consistent with Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4), Nasdaq will provide the Company a cure period in order to regain compliance (i) until the earlier of the Company's next annual shareholders' meeting or July 28, 2023, or (ii) if the next annual shareholders' meeting is held before January 24, 2023, then the Company must evidence compliance no later than January 24, 2023.

The Board will undertake to identify and select a suitable candidate or candidates to join the Board who would both qualify as "independent" and meet the audit committee criteria set forth in Nasdaq Listing Rule 5605. The Board intends to regain compliance with the independent director and audit committee requirements before the end of the cure period described above.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses